ATE496617T1 - Abgabesystem mit gesteuerter freisetzung zur nasalen anwendung von neurotransmittern - Google Patents

Abgabesystem mit gesteuerter freisetzung zur nasalen anwendung von neurotransmittern

Info

Publication number: ATE496617T1
Authority: AT; Austria
Prior art keywords: neurotransmitters; delivery system; controlled release; release delivery; nasal use
Prior art date: 2006-10-04

Application number

AT07818492T

Other languages

English (en)

Inventor

Claudia Mattern

Original Assignee

M & P Patent Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-10-04

Filing date

2007-09-27

Publication date

2011-02-15

2007-09-27 Application filed by M & P Patent Ag filed Critical M & P Patent Ag

2011-02-15 Application granted granted Critical

2011-02-15 Publication of ATE496617T1 publication Critical patent/ATE496617T1/de

Links

239000002858 neurotransmitter agent Substances 0.000 title abstract 3
238000013270 controlled release Methods 0.000 title 1
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 abstract 2
210000004556 brain Anatomy 0.000 abstract 2
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 abstract 2
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 abstract 2
ORNBQBCIOKFOEO-YQUGOWONSA-N Pregnenolone Natural products O=C(C)[C@@H]1[C@@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC3)C[C@@H](O)CC4)CC2)CC1 ORNBQBCIOKFOEO-YQUGOWONSA-N 0.000 abstract 1
239000004480 active ingredient Substances 0.000 abstract 1
229960003638 dopamine Drugs 0.000 abstract 1
238000009472 formulation Methods 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
ORNBQBCIOKFOEO-QGVNFLHTSA-N pregnenolone Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 ORNBQBCIOKFOEO-QGVNFLHTSA-N 0.000 abstract 1
229960000249 pregnenolone Drugs 0.000 abstract 1
229960003387 progesterone Drugs 0.000 abstract 1
239000000186 progesterone Substances 0.000 abstract 1
229940076279 serotonin Drugs 0.000 abstract 1
210000002966 serum Anatomy 0.000 abstract 1
230000002459 sustained effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Emergency Medicine (AREA)
Addiction (AREA)
Psychiatry (AREA)
Otolaryngology (AREA)
Dispersion Chemistry (AREA)
Hospice & Palliative Care (AREA)
Pain & Pain Management (AREA)
Psychology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Plant Substances (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT07818492T 2006-10-04 2007-09-27 Abgabesystem mit gesteuerter freisetzung zur nasalen anwendung von neurotransmittern ATE496617T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US82810906P	2006-10-04	2006-10-04
PCT/EP2007/008409 WO2008040488A1 (en)	2006-10-04	2007-09-27	Controlled release delivery system for nasal application of neurotransmitters

Publications (1)

Publication Number	Publication Date
ATE496617T1 true ATE496617T1 (de)	2011-02-15

Family

ID=38799348

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT07818492T ATE496617T1 (de)	2006-10-04	2007-09-27	Abgabesystem mit gesteuerter freisetzung zur nasalen anwendung von neurotransmittern

Country Status (19)

Country	Link
US (4)	US20090227550A1 (de)
EP (1)	EP2068825B1 (de)
JP (1)	JP5248510B2 (de)
KR (1)	KR101307133B1 (de)
CN (1)	CN101600417B (de)
AT (1)	ATE496617T1 (de)
AU (1)	AU2007304471B2 (de)
BR (1)	BRPI0717509B8 (de)
CA (1)	CA2664427C (de)
DE (1)	DE602007012276D1 (de)
DK (1)	DK2068825T3 (de)
ES (1)	ES2358619T3 (de)
MX (1)	MX2009003654A (de)
NO (1)	NO339802B1 (de)
PL (1)	PL2068825T3 (de)
PT (1)	PT2068825E (de)
RU (1)	RU2480208C2 (de)
WO (1)	WO2008040488A1 (de)
ZA (1)	ZA200902902B (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2258694T3 (es)	2003-11-11	2006-09-01	Mattern, Udo	Sistema de administracion de liberacion controlada de hormonas sexuales para aplicaciones nasales.
US8784869B2 (en)	2003-11-11	2014-07-22	Mattern Pharma Ag	Controlled release delivery system for nasal applications and methods of treatment
US20060140820A1 (en)	2004-12-28	2006-06-29	Udo Mattern	Use of a container of an inorganic additive containing plastic material
DK2068825T3 (da)	2006-10-04	2011-05-16	M & P Patent Ag	Kontrolleret frisætningstilførselssystem til nasal påføring af neurotransmittere
US20130040923A1 (en)	2011-05-13	2013-02-14	Trimel Pharmaceuticals Corporation	Intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US9757388B2 (en)	2011-05-13	2017-09-12	Acerus Pharmaceuticals Srl	Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
ES2825799T3 (es)	2011-05-13	2021-05-17	Acerus Biopharma Inc	Formulaciones en gel de testosterona intranasal de concentración de dosis más baja y uso de las mismas para tratar anorgasmia o trastorno del deseo sexual hipoactivo
US20130045958A1 (en)	2011-05-13	2013-02-21	Trimel Pharmaceuticals Corporation	Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
MX2013013369A (es) *	2011-05-15	2014-10-17	Trimel Biopharma Srl	Formulaciones de gel bioadhesivo de testosterona intranasal y uso del mismo para tratar hipogonadismo masculino.
US9301920B2 (en)	2012-06-18	2016-04-05	Therapeuticsmd, Inc.	Natural combination hormone replacement formulations and therapies
EP2782584B1 (de)	2011-11-23	2021-06-09	TherapeuticsMD, Inc.	Natürliche kombinierte hormonersatzformulierungen und -therapien
US10806740B2 (en)	2012-06-18	2020-10-20	Therapeuticsmd, Inc.	Natural combination hormone replacement formulations and therapies
US20130338122A1 (en)	2012-06-18	2013-12-19	Therapeuticsmd, Inc.	Transdermal hormone replacement therapies
US20150196640A1 (en)	2012-06-18	2015-07-16	Therapeuticsmd, Inc.	Progesterone formulations having a desirable pk profile
US10806697B2 (en)	2012-12-21	2020-10-20	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
DE102012015248A1 (de) *	2012-08-05	2014-02-06	Naum Goldstein	Verfahren zur Einbringung biologisch aktiver Substanzen ins Gehirn
US11246875B2 (en)	2012-12-21	2022-02-15	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en)	2012-12-21	2022-03-08	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en)	2012-12-21	2020-02-25	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en)	2012-12-21	2015-11-10	Therapeuticsmd, Inc.	Soluble estradiol capsule for vaginal insertion
US10537581B2 (en)	2012-12-21	2020-01-21	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en)	2012-12-21	2019-11-12	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US11744838B2 (en)	2013-03-15	2023-09-05	Acerus Biopharma Inc.	Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
AR100562A1 (es)	2014-05-22	2016-10-12	Therapeuticsmd Inc	Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal
US10699130B2 (en) *	2014-07-25	2020-06-30	Nec Corporation	Image processing apparatus, monitoring system, image processing method, and program
KR20170040209A (ko)	2014-07-29	2017-04-12	쎄러퓨틱스엠디, 인코퍼레이티드	경피 크림
US10328087B2 (en)	2015-07-23	2019-06-25	Therapeuticsmd, Inc.	Formulations for solubilizing hormones
KR20180126582A (ko)	2016-04-01	2018-11-27	쎄러퓨틱스엠디, 인코퍼레이티드	스테로이드 호르몬 약제학적 조성물
WO2017173044A1 (en)	2016-04-01	2017-10-05	Therapeuticsmd Inc.	Steroid hormone compositions in medium chain oils
US11903951B2 (en) *	2016-06-03	2024-02-20	M et P Pharma AG	Nasal pharmaceutical compositions with a porous excipient
HUE063346T2 (hu) *	2017-01-20	2024-01-28	M et P Pharma AG	Nazális gyógyszerészeti készítmények légszennyezõ anyagoknak való kitettség kockázatainak csökkentésére
KR102904262B1 (ko)	2018-01-11	2025-12-24	엠 이티 피 파마 아게	탈수초성 질환의 치료
WO2019148140A2 (en) *	2018-01-26	2019-08-01	Wu Joseph C	Implantable biomaterials that enhance stem cell survival and function
CA3066284A1 (en)	2018-04-09	2019-10-17	Katana Pharmaceuticals, Inc.	Oxytocin compositions and methods of use
WO2019202504A1 (en) *	2018-04-17	2019-10-24	M et P Pharma AG	Compositions and methods for intranasal delivery of pregnenolone
MX2023005822A (es) *	2020-11-19	2023-05-31	Acousia Therapeutics Gmbh	Composicion de gel no acuoso.

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE943792C (de)	1949-02-18	1956-06-01	Organon Nv	Verfahren zur Herstellung von injizierbaren Hormonpraeparaten
GB1032874A (en)	1964-02-13	1966-06-15	Du Pont	Stabilized polyoxymethylenes
US3769424A (en)	1970-10-01	1973-10-30	Merck & Co Inc	Composition and method of treating dopamine deficiency in brain tissue
US4123417A (en)	1974-10-10	1978-10-31	Mobil Oil Corporation	Low density polyethylene toughened with ethylene/propylene copolymer
NL7506407A (nl)	1975-05-30	1976-12-02	Akzo Nv	Werkwijze ter bereiding van een oraal werkzaam far- maceutisch preparaat.
NL7510104A (nl)	1975-08-27	1977-03-01	Akzo Nv	Werkwijze ter bereiding van een oraal werkzaam farmaceutisch preparaat.
DE2548413A1 (de)	1975-10-27	1977-04-28	Schering Ag	Depotpraeparate in oeliger ungesaettigter loesung zur intramuskulaeren injektion
US4315925A (en)	1980-05-30	1982-02-16	University Of Kentucky Research Foundation	Method of administering natural female sex hormones
DE3151912A1 (de)	1981-12-23	1983-06-30	Schering Ag, 1000 Berlin Und 4619 Bergkamen	Neue ergolin-aminoderivate, verfahren zu ihrer herstellung und deren verwendung als arzneimittel
US4546882A (en)	1983-02-07	1985-10-15	American Can Company	Package having oil-containing product
US4581255A (en) *	1983-08-30	1986-04-08	Abitibi-Price Corporation	Method of making simulated ceramic tile
JPS60136283U (ja)	1984-02-22	1985-09-10	株式会社シマノ	キヤリバ−ブレ−キ
US4581225A (en)	1984-04-25	1986-04-08	Eli Lilly And Company	Sustained release intranasal formulation and method of use thereof
ZA852884B (en) *	1984-04-25	1986-11-26	Lilly Co Eli	Sustained release intranasal formulation and method of use thereof
US4812448A (en)	1984-10-22	1989-03-14	Knepper Paul A	Method for the prevention of ocular hypertension, treatment of glaucoma and treatment of ocular hypertension
US4752425A (en)	1986-09-18	1988-06-21	Liposome Technology, Inc.	High-encapsulation liposome processing method
US4786678A (en)	1986-12-29	1988-11-22	Mobil Oil Corporation	Method of producing films from polyethylene resin, an additive and a second polymeric resin
US5049387A (en)	1987-03-09	1991-09-17	Alza Corporation	Inducing skin tolerance to a sensitizing drug
US5690954A (en)	1987-05-22	1997-11-25	Danbiosyst Uk Limited	Enhanced uptake drug delivery system having microspheres containing an active drug and a bioavailability improving material
JPS646716A (en)	1987-06-27	1989-01-11	Suzuki Motor Co	Displacement measuring apparatus
JP2543708B2 (ja)	1987-07-13	1996-10-16	旭化成工業株式会社	難溶性薬物を封入したエマルジョン製剤の製造方法
JPH01160916A (ja) *	1987-12-18	1989-06-23	Tanabe Seiyaku Co Ltd	ドーパミン経鼻投与製剤
NL8801670A (nl)	1988-07-01	1990-02-01	Walter Adrianus Josephus Johan	Farmaceutisch preparaat.
GB2237510B (en)	1989-11-04	1993-09-15	Danbiosyst Uk	Small particle drug compositions for nasal administration
US5397771A (en)	1990-05-10	1995-03-14	Bechgaard International Research And Development A/S	Pharmaceutical preparation
US5624960A (en) *	1991-01-23	1997-04-29	Isis Pharma Gmbh	Orally administrable drugs for the treatment of central dopamine deficiency conditions
US5500261A (en)	1991-05-24	1996-03-19	Kao Corporation	Resin composition and a container
US5221698A (en)	1991-06-27	1993-06-22	The Regents Of The University Of Michigan	Bioactive composition
DE4218291A1 (de)	1992-06-03	1993-12-09	Mattern Et Partner Pharmazeuti	Dosierspray für pernasale Applikation
US5756071A (en)	1992-06-03	1998-05-26	Arrowdean Limited	Method for nasally administering aerosols of therapeutic agents to enhance penetration of the blood brain barrier
SE9301171D0 (sv)	1993-04-07	1993-04-07	Ab Astra	Pharmaceutical composition containing lipophilic drugs
WO1995020945A1 (en)	1994-02-04	1995-08-10	Scotia Lipidteknik Ab	Lipophilic carrier preparations
GB9405304D0 (en)	1994-03-16	1994-04-27	Scherer Ltd R P	Delivery systems for hydrophobic drugs
US5635203A (en)	1994-09-29	1997-06-03	Alza Corporation	Transdermal device having decreased delamination
AU3618795A (en)	1994-10-05	1996-05-02	Hisamitsu Pharmaceutical Co., Inc.	Drug compounding ingredients comprising n-substituted-o-toluidine derivative and percutaneously absorbable preparation
US5747058A (en)	1995-06-07	1998-05-05	Southern Biosystems, Inc.	High viscosity liquid controlled delivery system
GB9608719D0 (en)	1996-04-26	1996-07-03	Scherer Ltd R P	Pharmaceutical compositions
GB9707934D0 (en)	1997-04-18	1997-06-04	Danbiosyst Uk	Improved delivery of drugs to mucosal surfaces
US6624200B2 (en)	1998-08-25	2003-09-23	Columbia Laboratories, Inc.	Bioadhesive progressive hydration tablets
US5877216A (en)	1997-10-28	1999-03-02	Vivus, Incorporated	Treatment of female sexual dysfunction
US5897894A (en)	1997-12-29	1999-04-27	General Mills, Inc.	Microwave popcorn with coarse salt crystals and method of preparation
AU3843999A (en) *	1998-05-07	1999-11-23	Elan Corporation, Plc	Solvent/cosolvent free microemulsion and emulsion preconcentrate drug delivery systems
FR2779438B1 (fr)	1998-06-03	2004-12-24	Jean Marc Aiache	Gel stable, son procede de preparation, et compositions pharmaceutiques le comprenant
GB9823246D0 (en)	1998-10-24	1998-12-16	Danbiosyst Uk	A nasal drug delivery composition
US6838091B2 (en) *	1998-12-18	2005-01-04	Abbott Laboratories	Formulations comprising lipid-regulating agents
US6319905B1 (en) *	1998-12-29	2001-11-20	Cell Genesys, Inc.	Method of controlling L-Dopa production and of treating dopamine deficiency
GB9828861D0 (en) *	1998-12-31	1999-02-17	Danbiosyst Uk	Compositions
US6294192B1 (en)	1999-02-26	2001-09-25	Lipocine, Inc.	Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6761903B2 (en)	1999-06-30	2004-07-13	Lipocine, Inc.	Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US6248363B1 (en)	1999-11-23	2001-06-19	Lipocine, Inc.	Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
JP2002541111A (ja)	1999-04-01	2002-12-03	アクゾ・ノベル・エヌ・ベー	ウンデカン酸テストステロンとヒマシ油を含む調合物
US6287588B1 (en)	1999-04-29	2001-09-11	Macromed, Inc.	Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof
JP5184727B2 (ja)	1999-06-11	2013-04-17	ワトソンファーマシューティカルズ，インコーポレイテッド	女性への非経口アンドロゲンステロイドの投与
WO2001021154A2 (en)	1999-09-21	2001-03-29	Rtp Pharma Inc.	Surface modified particulate compositions of biologically active substances
US6720001B2 (en)	1999-10-18	2004-04-13	Lipocine, Inc.	Emulsion compositions for polyfunctional active ingredients
US6231662B1 (en)	1999-10-25	2001-05-15	George K. Atkinson	Surface treatments for titanium dioxide and other industrial pigments
AU1261501A (en)	1999-12-06	2001-06-18	Stanley L. Gore	Compositions and methods for intranasal delivery of active agents to the brain
US8980290B2 (en)	2000-08-03	2015-03-17	Antares Pharma Ipl Ag	Transdermal compositions for anticholinergic agents
US20030139384A1 (en)	2000-08-30	2003-07-24	Dudley Robert E.	Method for treating erectile dysfunction and increasing libido in men
US20020072509A1 (en)	2000-10-11	2002-06-13	Stein Donald Gerald	Methods for the treatment of a traumatic central nervous system injury
TW586946B (en)	2000-12-22	2004-05-11	Novartis Ag	Process to improve stability
US20020114933A1 (en)	2000-12-28	2002-08-22	Gould Richard J.	Grease masking packaging materials and methods thereof
US6730330B2 (en)	2001-02-14	2004-05-04	Gw Pharma Limited	Pharmaceutical formulations
WO2002069906A2 (en)	2001-03-06	2002-09-12	Cellegy Pharmaceuticals, Inc.	Compounds and methods for the treatment of urogenital disorders
US20040028613A1 (en) *	2001-06-25	2004-02-12	Nastech Pharmaceutical Company Inc	Dopamine agonist formulations for enhanced central nervous system delivery
US6833478B2 (en) *	2001-07-13	2004-12-21	Sri International	N,N-dinitramide salts as solubilizing agents for biologically active agents
WO2003020517A1 (en)	2001-08-30	2003-03-13	Toray Plastics (America), Inc.	Polyolefin oil resistant film using porous particles
US6815506B2 (en)	2001-10-15	2004-11-09	Jsr Corporation	Oil-resistant thermoplastic elastomer composition and moldings using the same
DE60320940D1 (de)	2002-02-01	2008-06-26	Pfizer Prod Inc	Pharmazeutische zusammensetzungen amorpher dispersionen von wirkstoffen und lipophiler mikrophasenbildender materialien
US6855332B2 (en)	2002-07-03	2005-02-15	Lyfjathroun Hf.	Absorption promoting agent
US7029657B2 (en)	2002-08-02	2006-04-18	Balance Pharmaceuticals, Inc.	Nasal spray steroid formulation and method
US6958142B2 (en)	2002-08-02	2005-10-25	Balance Pharmaceuticals, Inc.	Nasal spray formulation and method
US20040259852A1 (en)	2003-06-18	2004-12-23	White Hillary D.	Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome
ES2258694T3 (es)	2003-11-11	2006-09-01	Mattern, Udo	Sistema de administracion de liberacion controlada de hormonas sexuales para aplicaciones nasales.
US8784869B2 (en)	2003-11-11	2014-07-22	Mattern Pharma Ag	Controlled release delivery system for nasal applications and methods of treatment
US20050153946A1 (en)	2003-12-24	2005-07-14	Collegium Pharmaceuticals, Inc.	Temperature-stable formulations, and methods of development thereof
US20060140820A1 (en)	2004-12-28	2006-06-29	Udo Mattern	Use of a container of an inorganic additive containing plastic material
US20070134332A1 (en) *	2005-11-21	2007-06-14	Medivas, Llc	Polymer particles for delivery of macromolecules and methods of use
DK2068825T3 (da)	2006-10-04	2011-05-16	M & P Patent Ag	Kontrolleret frisætningstilførselssystem til nasal påføring af neurotransmittere

2007
- 2007-09-27 DK DK07818492.6T patent/DK2068825T3/da active
- 2007-09-27 WO PCT/EP2007/008409 patent/WO2008040488A1/en not_active Ceased
- 2007-09-27 AU AU2007304471A patent/AU2007304471B2/en not_active Ceased
- 2007-09-27 RU RU2009116609/15A patent/RU2480208C2/ru active
- 2007-09-27 EP EP07818492A patent/EP2068825B1/de active Active
- 2007-09-27 BR BRPI0717509A patent/BRPI0717509B8/pt not_active IP Right Cessation
- 2007-09-27 ZA ZA200902902A patent/ZA200902902B/xx unknown
- 2007-09-27 DE DE602007012276T patent/DE602007012276D1/de active Active
- 2007-09-27 ES ES07818492T patent/ES2358619T3/es active Active
- 2007-09-27 CA CA2664427A patent/CA2664427C/en active Active
- 2007-09-27 AT AT07818492T patent/ATE496617T1/de active
- 2007-09-27 KR KR1020097009279A patent/KR101307133B1/ko not_active Expired - Fee Related
- 2007-09-27 JP JP2009530783A patent/JP5248510B2/ja not_active Expired - Fee Related
- 2007-09-27 MX MX2009003654A patent/MX2009003654A/es active IP Right Grant
- 2007-09-27 PT PT07818492T patent/PT2068825E/pt unknown
- 2007-09-27 PL PL07818492T patent/PL2068825T3/pl unknown
- 2007-09-27 CN CN2007800448143A patent/CN101600417B/zh not_active Expired - Fee Related
2009
- 2009-04-06 US US12/418,917 patent/US20090227550A1/en not_active Abandoned
- 2009-04-28 NO NO20091695A patent/NO339802B1/no unknown
2011
- 2011-07-30 US US13/194,926 patent/US9186320B2/en active Active
2015
- 2015-10-13 US US14/881,332 patent/US9801834B2/en active Active
2017
- 2017-09-26 US US15/716,337 patent/US20180200203A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US9186320B2 (en)	2015-11-17
US20180200203A1 (en)	2018-07-19
NO20091695L (no)	2009-06-23
PT2068825E (pt)	2011-02-11
JP2010505778A (ja)	2010-02-25
MX2009003654A (es)	2009-04-22
PL2068825T3 (pl)	2011-06-30
DK2068825T3 (da)	2011-05-16
DE602007012276D1 (de)	2011-03-10
AU2007304471A1 (en)	2008-04-10
CN101600417B (zh)	2012-05-30
BRPI0717509A2 (pt)	2016-05-17
AU2007304471B2 (en)	2012-09-06
KR101307133B1 (ko)	2013-09-12
ES2358619T3 (es)	2011-05-12
BRPI0717509B1 (pt)	2019-11-26
WO2008040488A1 (en)	2008-04-10
US20090227550A1 (en)	2009-09-10
CA2664427C (en)	2012-06-05
BRPI0717509B8 (pt)	2021-05-25
US9801834B2 (en)	2017-10-31
KR20090098958A (ko)	2009-09-18
CN101600417A (zh)	2009-12-09
EP2068825B1 (de)	2011-01-26
US20120009249A1 (en)	2012-01-12
US20160089347A1 (en)	2016-03-31
RU2009116609A (ru)	2010-11-10
EP2068825A1 (de)	2009-06-17
JP5248510B2 (ja)	2013-07-31
ZA200902902B (en)	2010-07-28
CA2664427A1 (en)	2008-04-10
NO339802B1 (no)	2017-02-06
RU2480208C2 (ru)	2013-04-27
HK1137658A1 (en)	2010-08-06

Legal Events

Date

Code

Title

Description

2011-08-15

UEP

Publication of translation of european patent specification

Ref document number: 2068825

Country of ref document: EP

Publication	Publication Date	Title
DE602007012276D1 (de)	2011-03-10	Abgabesystem mit gesteuerter freisetzung zur nasalen anwendung von neurotransmittern
EP4512394A3 (de)	2025-10-22	Darreichungsform und verwendung davon
PH12014502516B1 (en)	2015-01-12	Formulations and methods for vaginal delivery of antiprogestins
MX2015009773A (es)	2016-08-05	Moduladores de receptores nmda de espiro-lactama y sus usos.
PH12015501598A1 (en)	2015-10-19	Spiro-lactam nmda receptor modulators and uses thereof
BRPI0416370A (pt)	2007-05-22	sistema de distribuição de liberação controlada para aplicações nasais
MX2015009778A (es)	2016-02-09	Moduladores de receptores nmda de espiro-lactama y sus usos.
MY163809A (en)	2017-10-31	Transdermal drug delivery system containing donepezil
BR112015018087A8 (pt)	2021-06-22	composto, composição farmacêutica e uso
BR112014011841A2 (pt)	2017-05-02	material de entrega de fármacos hidrofóbicos, método para a produção do mesmo e métodos para a entrega de uma composição de entrega de fármacos
MX2015015589A (es)	2016-07-05	Composiciones y metodos para el suministro de agentes activos hidrófobos.
MX2015016416A (es)	2016-03-03	Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades.
MX361349B (es)	2018-12-04	Moduladores del receptor x del higado (lxr) para el tratamiento de enfermedades, trastornos y condiciones dérmicas.
MX2009006447A (es)	2009-07-27	Composicion farmaceutica de liberacion sostenida a largo plazo que contiene suspension acuosa de bisfosfonato.
CA3010829A1 (en)	2017-07-13	Gel compositions for transdermal delivery to maximize drug concentrations in the stratum corneum and serum and methods of use thereof
MX2015008021A (es)	2016-03-04	Composiciones y metodos para administracion transdermica de hormonas y otros agentes medicos.
CO7101247A2 (es)	2014-10-31	Formulaciones de ácido poliinosínico-policitidílico (poli(i:c)) para el tratamiento de infecciones de las vías respiratorias altas
PH12015500653B1 (en)	2015-05-11	Combination drug comprising gemigliptin and metformin, and method for the preparation thereof
EA201591188A1 (ru)	2016-04-29	Доставка глатирамера ацетата через слизистую оболочку
EA201591415A1 (ru)	2016-01-29	Фармацевтические композиции, включающие многокомпонентные кристаллические частицы, подходящие для применения в ингаляционной терапии
BR112012014107B8 (pt)	2021-05-25	sistema terapêutico transdérmico (tts) e processo de produção de tts
WO2009076413A3 (en)	2009-08-06	Methods, devices and compositions for controlled drug delivery to injured myocardium
MY166972A (en)	2018-07-27	Transdermal delivery system containing galantamine or salts thereof
IN2014CN02343A (de)	2015-06-19
ZA202003904B (en)	2025-04-30	Drug delivery system